Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015)

References

• Staschke KA, Dong S, Saba J, et al. IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease. J Immunol. 2009;183:568–577.
   PubMed Web of Science ®Google Scholar
• Song KW, Talamas FX, Suttmann RT, et al. The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells. Mol Immunol. 2009;46:1458–1466.
   PubMed Web of Science ®Google Scholar
• Pauls E, Nanda SK, Smith H, et al. Two phases of inflammatory mediator production defined by the study of IRAK2 and IRAK1 knock-in mice. J Immunol. 2013;191:2717–2730.
   PubMed Web of Science ®Google Scholar
• Li SY, Strelow A, Fontana EJ, et al. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Nat Acad Sci U S A. 2002;99:5567–5572.
   PubMed Web of Science ®Google Scholar
• Brzezinska AA, Johnson JL, Munafo DB, et al. Signalling mechanisms for Toll-like receptor-activated neutrophil exocytosis: key roles for interleukin-1-receptor-associated kinase-4 and phosphatidylinositol 3-kinase but not Toll/IL-1 receptor (TIR) domain-containing adaptor inducing IFN-beta (TRIF). Immunology. 2009;127:386–397.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499–511.
   PubMed Web of Science ®Google Scholar
• Suzuki N, Saito T. IRAK-4 - a shared NF-kappa B activator in innate and acquired immunity. Trends Immunol. 2006;27:566–572.
   PubMed Web of Science ®Google Scholar
• O’Neill LAJ. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev. 2008;226:10–18.
   PubMed Web of Science ®Google Scholar
• Zhou F, He XW, Iwakura Y, et al. Arthritis in mice that are deficient in interleukin-1 receptor antagonist is dependent on genetic background. Arthritis Rheum. 2005;52:3731–3738.
   PubMed Web of Science ®Google Scholar
• Li X. IRAK4 in TLR/IL-1R signaling: possible clinical applications. Eur J Immunol. 2008;38:614–618.
   PubMed Web of Science ®Google Scholar
• Joosten LAB, Netea MG. Interleukin-1 receptor-associated kinase 4 links innate immunity to the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2009;60:1571–1574.
   PubMed Web of Science ®Google Scholar
• Ferraccioli G, Bracci-Laudiero L, Alivernini S, et al. Interleukin-1 beta and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. Mol Med. 2010;16:552–557.
   PubMed Web of Science ®Google Scholar
• Carrier Y, Ma H-L, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Derm. 2011;131:2428–2437.
   PubMed Web of Science ®Google Scholar
• Coccia M, Harrison OJ, Schiering C, et al. IL-1 beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med. 2012;209:1595–1609.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yin H, Zhao M, et al. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol. 2013;47:136–147.
   Web of Science ®Google Scholar
• Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633–652.
   PubMed Web of Science ®Google Scholar
• Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol. 2013;9:154–163.
   PubMed Web of Science ®Google Scholar
• Koziczak-Holbro M, Littlewood-Evans A, Poellinger B, et al. The critical role of kinase activity of interleukin-1 receptor-associated kinase 4 in animal models of joint inflammation. Arthritis Rheum. 2009;60:1661–1671.
   PubMed Web of Science ®Google Scholar
• Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 2003;299:2076–2079.
   PubMed Web of Science ®Google Scholar
• Von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science. 2008;321:691–696.
   PubMed Web of Science ®Google Scholar
• Picard C, von Bernuth H, Ghandil P, et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine. 2010;89:403–425.
   PubMed Web of Science ®Google Scholar
• Frans G, Moens L, Schrijvers R, et al. PID in disguise: molecular diagnosis of IRAK-4 deficiency in an adult previously misdiagnosed with autosomal dominant hyper IgE syndrome. J Clin Immunol. 2015;35:739–744.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–U33.
   PubMed Web of Science ®Google Scholar
• Powers JP, Li SY, Jaen JC, et al. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006;16:2842–2845.
   PubMed Web of Science ®Google Scholar
• Kelly PN, Romero DL, Yang Y, et al. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015;212:2189–2201.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wesche H, Stevens T, et al. IRAK-4 inhibitors for inflammation. Curr Top Med Chem. 2009;9:724–737.
   PubMed Web of Science ®Google Scholar
• Hynes J Jr., Nair SK. Advances in the discovery of small-molecule IRAK4 inhibitors. Annu Rep Med Chem. 2014;49:117–133.
   Web of Science ®Google Scholar
• Chaudhary D, Robinson S, Romero DL. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. J Med Chem. 2015;58:96–110.
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun D, Johnstone S, et al. Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2015;25:5546–5550.
   PubMed Web of Science ®Google Scholar
• Ares Trading SA Pyrazolylpyrimidine derivatives as IRAK inhibitors and their preparation. WO2014008992A1. 2014.
   Google Scholar
• Aurigene Discovery Technologies Ltd. Preparation of bicyclic heterocycles as inhibitors of IRAK4 and other protein kinases for therapy. WO2013042137A1. 2013.
   Google Scholar
• Aurigene Discovery Technologies Ltd. Bicyclic heterocyclyl derivatives as IRAK4 inhibitors and their preparation. WO2015104688A1. 2015.
   Google Scholar
• Aurigene Discovery Technologies Ltd. Indazole compounds as IRAK4 inhibitors and their preparation. WO2015104662A1. 2015.
   Google Scholar
• Aurigene Discovery Technologies Ltd. Substituted indazole compounds as IRAK4 inhibitors. WO2015193846A1. 2015.
   Google Scholar
• Curis press release. [cited 2016Mar 12]. Available from: http://investors.curis.com/releasedetail.cfm?releaseid=892180
   Google Scholar
• Bayer Pharma. Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments. WO2015091426A1. 2015.
   Google Scholar
• Biogen Idec MA Inc. Preparation of macrocyclic compounds as IRAK4 inhibitors useful for the treatment of inflammatory diseases. WO2014143672A1. 2014.
   Google Scholar
• Biogen MA Inc. Arenoazoles as IRAK4 inhibiting agents and their preparation. WO2016011390A1. 2016.
   Google Scholar
• Bristol-Myers Squibb Co. Preparation of triazolylpyridine derivatives for use as kinase inhibitors. WO2013106614A1. 2013.
   Google Scholar
• Bristol-Myers Squibb Co. Preparation of heterocyclylpyridine derivatives for use as kinase inhibitors. WO2013106641A1. 2013.
   Google Scholar
• Bristol-Myers Squibb Co. Preparation of heterocyclylpyridine derivatives for use as kinase inhibitors. WO2013106612A1. 2013.
   Google Scholar
• Bristol-Myers Squibb Co. Substituted pyridinecarboxamide compounds as kinase modulators and their preparation. WO2014074657A1. 2014.
   Google Scholar
• Bristol-Myers Squibb Co. Substituted pyridinecarboxamide compounds as kinase modulators and their preparation. WO2014074675A1. 2014.
   Google Scholar
• Bristol-Myers Squibb Co. Heteroaryl-substituted nicotinamide compounds as IRAK4 inhibitors and their preparation. WO2015103453A1. 2015.
   Google Scholar
• Hoffmann-La Roche AG F. Pyrazolo[1,5-a]pyrimidine and thieno[3,2-b]pyrimidine derivatives as IRAK4 modulators and their preparation. WO2012007375A1. 2012.
   Google Scholar
• Ligand Pharmaceuticals Inc. Preparation of heterocycle amines for treating inflammatory disorders. WO2012068546A1. 2012.
   Google Scholar
• Ligand Pharmaceuticals Pipeline. [cited 2016 Mar 12]. Available from: http://www.ligand.com/what-we-do/portfolio
   Google Scholar
• Vajda EG, Niecestro R, Zhi L, et al. IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B-cell lymphomas. 2015 AACR Annual Meeting; 2015 Apr 18-22; Abstract #785. Philadelphia (PA): American Association for Cancer Research.
   Google Scholar
• Vajda EG, Lin TH, Want B et al. Novel small molecule inhibitors of interleukin-1 receptor associated kinase-4 are effective in a preclinical model of arthritis. Presented at the Annual Meeting of the American College of Rheumatology; 2011; Chicago (IL): American College of Rheumatology; No. 836.
   Google Scholar
• Merck Serono SA Preparation of indazolyl triazole derivatives as IRAK inhibitors. WO2012084704A1. 2012.
   Google Scholar
• Merck Patent GmbH. Preparation of pyridazinone-amides derivatives for treating inflammatory disease, autoimmune disorder, cancer or multiple sclerosis. WO2014121931A1. 2014.
   Google Scholar
• Merck Patent GmbH. Macrocyclic pyridazinone derivatives as IRAK inhibitors and their preparation. WO2014121942A1. 2014.
   Google Scholar
• Merck Sharp & Dohme Corp. Preparation of amidopyrazole inhibitors of interleukin receptor-associated kinases. WO2012129258A1. 2012.
   Google Scholar
• Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity. WO2014058691A1. 2014.
   Google Scholar
• Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (IRAK-4). WO2015006181A1. 2015.
   Google Scholar
• McElroy WT, Tan Z, Ho G, et al. Potent and selective amidopyrazole inhibitors of IRAK4 that are efficacious in a rodent model of inflammation. ACS Med Chem Lett. 2015;6:677–682.
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Inc. Preparation of oxazole-carboxamide compounds as IRAK-4 inhibitors. WO2011043371A1. 2011.
   Google Scholar
• Merck Sharp & Dohme Corp. Preparation of pyrimidinyl- or pyridinyl-based compounds as inhibitors of IRAK4 activity for treatment of inflammation, proliferative disorders, and immune-related conditions. WO2014058685A1. 2014.
   Google Scholar
• Merck Sharp & Dohme Corp. Preparation of aminopyrimidinones as interleukin receptor-associated kinase inhibitors. WO2013066729A1. 2013.
   Google Scholar
• McElroy WT, Seganish WM, Herr RJ, et al. Discovery and hit to lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin receptor-associated kinase 4. Bioorg Med Chem Lett. 2015;25:1836–1841.
   PubMed Web of Science ®Google Scholar
• Seganish WM, McElroy WT, Herr RJ, et al. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4. Bioorg Med Chem Lett. 2015;25:3203–3207.
   PubMed Web of Science ®Google Scholar
• Seganish WM, Fischmann TO, Sherborne B, et al. Discovery and structure enabled synthesis of 2,6-diaminopyrimidin-4-one IRAK4 inhibitors. ACS Med Chem Lett. 2015;6:942–947.
   PubMed Web of Science ®Google Scholar
• Nimbus Iris, Inc. Preparation of substituted 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidines and analogs as IRAK inhibitors. WO2012097013A1. 2012.
   Google Scholar
• Nimbus Iris, Inc. Preparation of thieno[2,3-d]pyrimidine derivatives as IRAK inhibitors. WO2013106535A1. 2013.
   Google Scholar
• Wang Z, Liu J, Sudom A, et al. Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Structure. 2006;14:1835–1844.
   PubMed Web of Science ®Google Scholar
• Nimbus Iris, Inc. Preparation of thienopyrimidine compounds as IRAK inhibitors for treatment of cancer, neurodegenerative disorders, and other disease. WO2014011902A1. 2014.
   Google Scholar
• Nimbus Iris, Inc. Preparation of thienopyridine compounds as IRAK inhibitors and therapeutic uses thereof. WO2014011906A2. 2014.
   Google Scholar
• Nimbus Iris, Inc. Preparation of furano- and pyrrolo-pyrimidine and pyridine compounds as IRAK inhibitors and therapeutic uses thereof. WO2014011911A2. 2014.
   Google Scholar
• Nimbus Iris, Inc. Preparation of thiazolo[5,4-d]pyrimidine derivatives as IRAK kinase inhibitors and uses thereof. WO2015048281A1. 2015.
   Google Scholar
• Nimbus Iris, Inc. IRAK Inhibitors and Uses Thereof. WO2015164374A1. 2015.
   Google Scholar
• Nimbus press release. [cited 2016 Mar 12]. Available from: http://www.nimbustx.com/news-events/press-releases/nimbus-therapeutics-announces-global-license-agreement-genentech
   Google Scholar
• Tumey LN, Boschelli DH, Bhagirath N, et al. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4. Bioorg Med Chem Lett. 2014;24:2066–2072.
   PubMed Web of Science ®Google Scholar
• Tumey LN, Rao V, Bhagirath N, et al. Identification and optimization of a series of indolo[2,3-c]quinoline IRAK4 inhibitors. From Abstracts of Papers, 241st ACS National Meeting & Exposition, Anaheim, CA, 2011 Mar 27-31, MEDI-3.
   Google Scholar
• Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds as IRAK4 inhibitors and their preparation. WO2015150995A1. 2015.
   Google Scholar
• Lee K, Allais C, Ambler C, et al. Discovery of clinical candidate PF-06650833: a potent, selective, and efficient inhibitor of IRAK4 from fragment-based drug design. From Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA; 2016 Mar 13-17, MEDI-261.
   Google Scholar
• van der Fits L, Mourits S, Voerman JSA, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182:5836–5845.
   PubMed Web of Science ®Google Scholar
• In their 2014 Annual Report. BMS indicated an IRAK4 inhibitor in phase I trials (www.BMS.com), however in their 2015 Annual Report, no such trial is listed.
   Google Scholar
• Information on clinical status and indication has been obtained [cited 2016 Mar 17] from www.pfizer.com and clinicaltrials.gov
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Preparation of pyrazole compounds as IRAK-4 inhibitors for the treatment autoimmune disorders and other diseases. WO2015068856A1. 2015.
   Google Scholar
• Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nature Rev Drug Discov. 2002;1:309–315.
   PubMed Web of Science ®Google Scholar
• Cohen P, Alessi DR. Kinase drug discovery - what’s next in the field? ACS Chem Biol. 2012;8:96–104.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015;100:1–23.
   PubMed Web of Science ®Google Scholar
• Uematsu S, Sato S, Yamamoto M, et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-alpha induction. J Exp Med. 2005;201:915–923.
   PubMed Web of Science ®Google Scholar
• Chiang EY, Yu X, Grogan JL. Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for IRAK1/4 kinase activity across human cell types. J Immunol. 2011;186:1279–1288.
   PubMed Web of Science ®Google Scholar
• Cushing L, Stochaj W, Siegel M, et al. Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner. J Biol Chem. 2014;289:10865–10875.
   PubMed Web of Science ®Google Scholar
• Sun J, Li N, Oh K-S, et al. Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use. Sci Signal. 2016. doi:10.1126/scisignal.aab2191.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol. 2008;26:127–132.
   PubMed Web of Science ®Google Scholar